<sup>18</sup>F-FECH PET/CT to Assess Clinically Significant Disease in Prostate Cancer: Correlation With Maximum and Total Cancer Core Length Obtained via MRI-Guided Template Mapping Biopsies.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 27611962.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The objective of this study was to detect clinically significant and insignificant prostate cancer on <sup>18</sup>F-fluoroethylcholine (FECH) PET/CT and to correlate findings with transperineal template-guided prostate mapping (TPM) biopsy. Fifty-six lobes of the prostate were analyzed in 28 men who underwent FECH PET/CT and TPM. Whole-body images and pelvic images were acquired at 60 and 90 minutes after tracer administration. FECH PET/CT findings were correlated with TPM. Sensitivity, specificity, positive predictive values, negative predictive values, and AUC of dual phase FECH PET/CT were calculated. Mean age of the patients was 68.8 years (range, 53-79 years), and mean prostate-specific antigen level was 12.1 ng/mL (range, 0.6-45 ng/mL). Mean maximum cancer core length was 4.4 mm (median, 4 mm; range, 1-14 mm) and mean total cancer core length, 14.6 mm (median, 14.6 mm; range, 1-82 mm). Prostate cancer was identified in 38 lobes with a Gleason score of 6 in five lobes (13%), 7 in 27 lobes (71%), 8 in four lobes (11%), and 9 in two lobes (5%). FECH PET/CT showed findings of prostate cancer in 46/56 lobes (82%). The ranges for maximum standardized uptake value for 60- and 90-minute FECH PET/CT were 1.3-11.4 and 1.2-10.9, respectively. Clinically significant cancer was seen in 30 of 38 positive lobes; eight had clinically insignificant disease. For 60-minute imaging, the sensitivity, specificity, and ROC AUC were 75%, 75%, and 0.746 (95% CI, 0.612-0.853). For 90-minute imaging, the sensitivity, specificity, and ROC AUC were 73.7%, 58.3%, and 0.646 (95% CI, 0.498-0.776). Overall sensitivity, specificity, positive predictive value, and negative predictive value were 95%, 50%, 82.6%, and 80%, respectively. FECH PET/CT can detect prostate cancer and localizes TPM biopsy-proven clinically significant prostate cancer with sensitivity of greater than 89.7%. Of the two imaging durations, 60-minute imaging is more sensitive and specific than 90-minute imaging.
Medical subject headings
- Choline
- Image-Guided Biopsy
- Magnetic Resonance Imaging, Interventional
- Positron Emission Tomography Computed Tomography
- Prostatic Neoplasms